These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30243571)

  • 1. The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
    Davies GA; Ghosh S; Oh DH; Manna M; Peters AC; Stewart CA; Stewart DA
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):829-835. PubMed ID: 30243571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of watchful waiting in patients with previously treated follicular lymphoma.
    Fujino T; Maruyama D; Maeshima AM; Saito Y; Ida H; Hosoba R; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Kuroda J; Izutsu K
    Cancer Med; 2022 May; 11(10):2106-2116. PubMed ID: 35129305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Yuda S; Miyagi Maeshima A; Taniguchi H; Ito Y; Hatta S; Suzuki T; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Eur J Haematol; 2021 Jul; 107(1):157-165. PubMed ID: 33905571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
    Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
    Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
    Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
    J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study).
    Miyamoto K; Fukuhara N; Maruyama D; Shibata T; Nakamura K; Ishizawa K; Tsukasaki K; Nagai H;
    Jpn J Clin Oncol; 2018 Aug; 48(8):777-780. PubMed ID: 29901705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low grade lymphoma: research progress and questions about treatment].
    Ishizawa K
    Rinsho Ketsueki; 2015 Oct; 56(10):2039-46. PubMed ID: 26458443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
    Batlevi CL; Sha F; Alperovich A; Ni A; Smith K; Ying Z; Soumerai JD; Caron PC; Falchi L; Hamilton A; Hamlin PA; Horwitz SM; Joffe E; Kumar A; Matasar MJ; Moskowitz AJ; Moskowitz CH; Noy A; Owens C; Palomba LM; Straus D; von Keudell G; Zelenetz AD; Seshan VE; Younes A
    Blood Cancer J; 2020 Jul; 10(7):74. PubMed ID: 32678074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
    Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.
    El-Galaly TC; Bilgrau AE; de Nully Brown P; Mylam KJ; Ahmad SA; Pedersen LM; Gang AO; Bentzen HH; Juul MB; Bergmann OJ; Pedersen RS; Nielsen BJ; Johnsen HE; Dybkaer K; Bøgsted M; Hutchings M
    Br J Haematol; 2015 May; 169(3):435-44. PubMed ID: 25709094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
    Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
    Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes.
    Andraos T; Ayoub Z; Nastoupil L; Pinnix C; Milgrom S; Gunther J; Ng SP; Fowler N; Neelapu S; Samaniego F; Dabaja B
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):381-389. PubMed ID: 30935940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
    Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR; Dillon H; Sinha R; Shenoy PJ; Levy D; Dawson K; Hirata JH; Flowers CR
    Ann Oncol; 2013 Feb; 24(2):441-448. PubMed ID: 23041589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
    Reagan PM; Friedberg JW
    Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.